These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32901316)

  • 21. Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.
    Naegelin Y; Naegelin P; von Felten S; Lorscheider J; Sonder J; Uitdehaag BMJ; Scotti B; Zecca C; Gobbi C; Kappos L; Derfuss T
    JAMA Neurol; 2019 Mar; 76(3):274-281. PubMed ID: 30615019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A retrospective observational study of rituximab treatment in multiple sclerosis patients in Cyprus.
    Leonidou E; Pantzaris M; Kleopa KA; Loizidou MA; Kyriakides T; Christou YP
    Postgrad Med; 2019 Sep; 131(7):486-489. PubMed ID: 31353999
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
    Zecca C; Bovis F; Novi G; Capobianco M; Lanzillo R; Frau J; Repice AM; Hakiki B; Realmuto S; Bonavita S; Curti E; Brambilla L; Mataluni G; Cavalla P; Di Sapio A; Signoriello E; Barone S; Maniscalco GT; Maietta I; Maraffi I; Boffa G; Malucchi S; Nozzolillo A; Coghe G; Mechi C; Salemi G; Gallo A; Sacco R; Cellerino M; Malentacchi M; De Angelis M; Lorefice L; Magnani E; Prestipino E; Sperli F; Brescia Morra V; Fenu G; Barilaro A; Abbadessa G; Signori A; Granella F; Amato MP; Uccelli A; Gobbi C; Sormani MP
    Mult Scler; 2020 Oct; 26(12):1519-1531. PubMed ID: 31573386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of rituximab in multiple sclerosis: Experience from a developing country.
    Mathew T; John SK; Kamath V; Murgod U; Thomas K; Baptist AA; Therambil M; Shaji A; Nadig R; Badachi S; Souza DD; Shivde S; Avati A; Sarma GRK; Sharath Kumar GG; Deepalam S; Parry GJ
    Mult Scler Relat Disord; 2020 Aug; 43():102210. PubMed ID: 32485634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany.
    Rauer S; Hoshi MM; Pul R; Wahl M; Schwab M; Haas J; Ellrichmann G; Krumbholz M; Tackenberg B; Saum KU; Buck F; Leemhuis J; Kretschmann A; Aktas O
    Clin Neurol Neurosurg; 2020 Oct; 197():106142. PubMed ID: 32920498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial.
    Romme Christensen J; Ratzer R; Börnsen L; Lyksborg M; Garde E; Dyrby TB; Siebner HR; Sorensen PS; Sellebjerg F
    Neurology; 2014 Apr; 82(17):1499-507. PubMed ID: 24682973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrathecal rituximab therapy in multiple sclerosis: review of evidence supporting the need for future trials.
    Bonnan M; Ferrari S; Bertandeau E; Demasles S; Krim E; Miquel M; Barroso B
    Curr Drug Targets; 2014; 15(13):1205-14. PubMed ID: 25355180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experience with rituximab therapy in a real-life sample of multiple sclerosis patients.
    Bellinvia A; Prestipino E; Portaccio E; Razzolini L; Fonderico M; Fratangelo R; Tudisco L; Pastò L; Amato MP
    Neurol Sci; 2020 Oct; 41(10):2939-2945. PubMed ID: 32350672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of intrathecal rituximab on biomarkers in multiple sclerosis.
    Topping J; Dobson R; Lapin S; Maslyanskiy A; Kropshofer H; Leppert D; Giovannoni G; Evdoshenko E
    Mult Scler Relat Disord; 2016 Mar; 6():49-53. PubMed ID: 27063622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).
    Rommer PS; Dörner T; Freivogel K; Haas J; Kieseier BC; Kümpfel T; Paul F; Proft F; Schulze-Koops H; Schmidt E; Wiendl H; Ziemann U; Zettl UK;
    J Neuroimmune Pharmacol; 2016 Mar; 11(1):1-8. PubMed ID: 26589235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Cree BAC; Cutter G; Wolinsky JS; Freedman MS; Comi G; Giovannoni G; Hartung HP; Arnold D; Kuhle J; Block V; Munschauer FE; Sedel F; Lublin FD;
    Lancet Neurol; 2020 Dec; 19(12):988-997. PubMed ID: 33222767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults.
    McAtee CL; Lubega J; Underbrink K; Curry K; Msaouel P; Barrow M; Muscal E; Lotze T; Srivaths P; Forbes LR; Allen C; Bernhardt MB
    JAMA Netw Open; 2021 Feb; 4(2):e2036321. PubMed ID: 33533931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis.
    Petrou P; Kassis I; Levin N; Paul F; Backner Y; Benoliel T; Oertel FC; Scheel M; Hallimi M; Yaghmour N; Hur TB; Ginzberg A; Levy Y; Abramsky O; Karussis D
    Brain; 2020 Dec; 143(12):3574-3588. PubMed ID: 33253391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population.
    Coban H; Germaine S; Dimaandal I; Haberli N; Padam C; Creed MA; Imitola J
    Mult Scler Relat Disord; 2021 Aug; 53():103021. PubMed ID: 34077828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Efficacy of Rituximab: Experience of a Single Multiple Sclerosis Center.
    Alldredge B; Jordan A; Imitola J; Racke MK
    Clin Neuropharmacol; 2018; 41(2):56-59. PubMed ID: 29389745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial.
    Ciampi E; Uribe-San-Martin R; Cárcamo C; Cruz JP; Reyes A; Reyes D; Pinto C; Vásquez M; Burgos RA; Hancke J
    BMC Neurol; 2020 May; 20(1):173. PubMed ID: 32380977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity.
    Juto A; Fink K; Al Nimer F; Piehl F
    Mult Scler Relat Disord; 2020 Jan; 37():101468. PubMed ID: 31683231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.
    Vermersch P; Brieva-Ruiz L; Fox RJ; Paul F; Ramio-Torrenta L; Schwab M; Moussy A; Mansfield C; Hermine O; Maciejowski M;
    Neurol Neuroimmunol Neuroinflamm; 2022 May; 9(3):. PubMed ID: 35190477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?
    Berntsson SG; Kristoffersson A; Boström I; Feresiadou A; Burman J; Landtblom AM
    Acta Neurol Scand; 2018 Oct; 138(4):327-331. PubMed ID: 29797711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland.
    Airas L; Nylund M; Mannonen I; Matilainen M; Sucksdorff M; Rissanen E
    Mult Scler Relat Disord; 2020 May; 40():101980. PubMed ID: 32066031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.